A randomised, double ‐blind, trial of the safety and efficacy of omarigliptin (a once‐weekly DPP‐4 inhibitor) in subjects with type 2 diabetes and renal impairment

ConclusionsIn this study in subjects with T2DM and RI, relative to placebo, omarigliptin provided clinically meaningful reductions in HbA1c, had a similar incidence of symptomatic hypoglycaemia and was generally well tolerated.

Source: International Journal of Clinical Practice - March 1, 2017 Category: Internal Medicine Authors: Antonio Chacra, Ira Gantz, Geraldine Mendizabal, Lucila Durlach, Edward A. O'Neill, Zachary Zimmer, Shailaja Suryawanshi, Samuel S. Engel, Eseng Lai Tags: ORIGINAL PAPER Source Type: research